Mercer Global Advisors Inc. ADV Sells 7,242 Shares of Moderna, Inc. (NASDAQ:MRNA)

Mercer Global Advisors Inc. ADV reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 49.5% during the fourth quarter, Holdings Channel reports. The firm owned 7,394 shares of the company’s stock after selling 7,242 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Moderna were worth $307,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MRNA. Czech National Bank lifted its position in shares of Moderna by 6.6% during the fourth quarter. Czech National Bank now owns 73,424 shares of the company’s stock valued at $3,053,000 after purchasing an additional 4,526 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Moderna by 13.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company’s stock valued at $623,000 after purchasing an additional 1,819 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Moderna during the fourth quarter valued at about $1,393,000. Arkadios Wealth Advisors lifted its position in shares of Moderna by 7.3% during the fourth quarter. Arkadios Wealth Advisors now owns 12,265 shares of the company’s stock valued at $510,000 after purchasing an additional 836 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of MRNA opened at $23.65 on Friday. The firm has a market cap of $9.15 billion, a price-to-earnings ratio of -2.55 and a beta of 1.99. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The firm has a 50 day moving average price of $28.05 and a 200-day moving average price of $35.78.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business’s quarterly revenue was down 35.3% on a year-over-year basis. During the same period in the previous year, the business posted ($3.07) EPS. As a group, equities research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MRNA. UBS Group decreased their price objective on shares of Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price for the company. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Finally, Royal Bank of Canada reduced their price objective on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.